Skip to main content

Viskase Holdings, Inc.

corporate_fare Company Profile

Viskase Holdings, Inc.

ENZN·OTC·Life Sciences·CIK 0000727510

Enzon Pharmaceuticals, Inc. is a public company acquisition vehicle, incorporated on May 11, 1983. Historically, the company generated royalty revenues from licensing agreements with other companies. These revenues were primarily related to sales of drug products that utilized Enzon's proprietary technology. For over ten years, Enzon has not conducted clinical operations and has maintained limited corporate operations. The company previously had a marketing agreement for the drug Vicineum, which could have generated future milestone and royalty payments if approved. However, the licensee for Vicineum was canceled by the counterparty to the marketing agreement, and Enzon's patent for Vicineum has since expired. Consequently, Enzon does not expect to earn any future material revenue from this product. On June 20, 2025, Enzon, EPSC Acquisition Corp. (a wholly owned subsidiary of Enzon), and Viskase Companies, Inc. entered into an Agreement and Plan of Merger, which was amended on October 24, 2025. Under this agreement, EPSC Acquisition Corp. will merge into Viskase, with Viskase surviving as a wholly owned subsidiary of Enzon. Following the merger, Enzon's pre-closing stockholders, including holders of its Series C Non-Convertible Redeemable Preferred Stock, are anticipated to hold 45% of Enzon's outstanding Common Stock, while Viskase's pre-closing stockholders will hold 55%.

Viskase Holdings, Inc. (OTC:ENZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ENZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-03, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ENZN spans 10-Q, SCHEDULE 13D/A, 8-K, 425.

Recent high-impact activity:

  • Viskase Q2 2026: Going Concern Warning as Losses Mount and Cash Dwindles
  • Viskase Holdings Narrows Q1 Net Loss by 50% to ($6.72M) Despite Revenue Decline
  • Carl Icahn's Entities Consolidate 93.7% Control of Viskase Holdings Post-Merger, Appoint Affiliates to Board
  • Viskase Holdings Completes Transformational Merger with Viskase Companies, Overhauls Leadership
  • Enzon Pharmaceuticals Completes Series C Preferred Stock Exchange Offer

Financial Snapshot

Quarter ended November 12, 2025
Net Income
-$824K
Diluted EPS
-$0.02
Op. Cash Flow
-$2.33M
Operating Income
-$1.3M
Cash & Equivalents
$43.26M
Debt / Equity
0.00×
Shares Outstanding
74.21M sh
Source: 10-Q · filed 2025-11-12 · accession 0001104659-25-110410

Recent Capital Actions

  • 2026-02-11 Proposed Exchange Offer +0 sh

    filed with the Securities and Exchange Commission (the “SEC”) on January 30, 2026 (as hereby amended and supplemented and together with any subsequent amendments and supplements thereto, this “Schedule TO”), is filed by…

  • 2026-01-30 Proposed Cash ↑ +$24.9M

    eeds of approximately $25.0 million pursuant to securities purchase agreements entered into in December 2025 and January 2026. $0.1 million of specific incremental costs were incurred attributable to the offerings of…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
Browse all tickers starting with E →

No longer listed

ENZN (Viskase Holdings, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ENZN - Latest Insights

ENZN
Aug 03, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
9
ENZN
May 04, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
8
ENZN
Mar 27, 2026, 7:48 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
ENZN
Mar 26, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
9
ENZN
Mar 25, 2026, 8:38 AM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 25, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
7
ENZN
Mar 24, 2026, 8:35 AM EDT
Filing Type: SC TO-I/A
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 425
Importance Score:
8
ENZN
Mar 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
ENZN
Mar 19, 2026, 4:07 PM EDT
Filing Type: SC TO-I/A
Importance Score:
7
ENZN
Mar 16, 2026, 4:10 PM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 11, 2026, 8:36 AM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 11, 2026, 8:31 AM EDT
Filing Type: SC TO-I/A
Importance Score:
7
ENZN
Mar 09, 2026, 4:13 PM EDT
Filing Type: 425
Importance Score:
7
ENZN
Mar 02, 2026, 4:56 PM EST
Filing Type: 10-K
Importance Score:
9
ENZN
Feb 27, 2026, 8:30 AM EST
Filing Type: SC TO-I/A
Importance Score:
8
ENZN
Feb 26, 2026, 4:05 PM EST
Filing Type: SC 14F1
Importance Score:
8
ENZN
Feb 11, 2026, 5:14 PM EST
Filing Type: 8-K
Importance Score:
9
ENZN
Jan 30, 2026, 6:02 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ENZN
Jan 30, 2026, 4:38 PM EST
Filing Type: 424B3
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets